The prevalence of annoying hyperhidrosis (HH) in patients with spinal cord traumatic lesions was investigated by a questionnaire. A total of 192 patients were sent the questionnaire, 154 patients answered, and 41 patients reported annoying sweating. Of these 41 patients, 13 had a somatic underlying cause and 28 indicated having annoying HH without a contributing somatic cause.
Introduction
Profuse hyperhidrosis (HH) is a condition that is seen in spinal cord injured (SCI) patients. Its aetiology is not completely understood, but it is generally referred to as a dysfunction of the autonomic nervous system and the thermoregulation due to the spinal cord lesion. 1 Excessive and annoying HH has pre sented a therapeutic problem, because the medical management is either unsuccessful or has unacceptable adverse effects. For example anticholinergic drugs may cause impairment of voiding, and adrenergic and ganglionic blocking drugs may cause pos tural hypotension.
Tashjian and Richter2 reported 2 cases of HH in SCI whom they treated successfully with dextropropoxyphene hydrochloride (DP). The authors recommended a further clinical trial on the subject.
Treatment of HH aims primarily at inhi biting activity in the sympathetic cholinergic innervated eccrine sweat glands. The me chanism of action of DP in this matter is purely speculative. Since DP acts as an agonist at opioid receptors, it may have the same effects on the autonomic nervous system as morphine. Animal studies with morphine have provided evidence to sup port the concept that opioids may act as weak ganglionic blocking agents,3 and morphine seems to attenuate the sympa thetic efferent discharge at the central ner vous system level in man. 4 We therefore carried out a double-blind, randomized, placebo controlled, cross-over trial to investigate the therapeutic effect of DP on annoying HH in SCI. Furthermore, to determine the prevalence of annoying HH, a questionnaire study was carried out at one of the two centres involved (The Paraplegic Function in Viborg).
Methods
Questionnaire study of the prevalence of annoying HH among SCI patients Using a questionnaire, 192 patients with SCI regularly controlled at the Paraplegic Func tion in Viborg were asked if they had previously experienced or currently had annoying HH, and, if so, whether they would like to receive medical treatment for it.
Study on the effect of D P All SCI patients with annoying HH who were regularly controlled at one of the 2 centres for SCI in Denmark were offered participation in the study. Patients were included if their HH had started after their SCI, and if they had had annoying HH at least once a week for one month or more.
Patients were excluded if (1) there was an obviously treatable somatic cause of the HH, for instance distention/inflammation of abdominal organs, infections, pressure sores, climacteric sweating etc; (2) HH occurred only in relation to autonomic hyperreflexia; (3) HH was present only in relation to bladder or bowel distention or emptying; (4) they were taking phenytoin, carbamazepine, pyridostigmine or DP; (5) they were allergic to DP; (6) they were found unable to cooperate or (7) they were alcoholics.
According to the Helsinki Declaration II, all patients were incubated after informed consent. Approval from the local scientific ethics committees was obtained. The pati ents were informed of the possible adverse effects of D P.
Before the trial all the patients were asked how often (in a week), and when (day and/or night) they had HH and how annoy ing it was (very annoying/annoying).
After randomisation the patients were allocated to either DP or placebo in the first Hyperhidrosis in spinal cord injury patients 185 trial period of 14 days, and this was followed immediately by cross-over to the second trial period of 14 days. DP was given in a slow release form (Abalgin Retard® cap sules 150 mg, Benzon Pharma A/S Copen hagen) twice a day to obtain a steady plasma concentration. Every morning and evening the patients recorded on a visual analogue scale how annoying they felt the sweat secretion had been during the preceding 12 hours. Furthermore, after each trial period, the patients were asked whether they had felt any change in sweat secretion during the night or the day. After the second period patients were asked if any of the trial periods were found to have beneficial ef fects on the sweating, and if they would like to continue either of the treatments. In addition, possible adverse effects were noted. Medical treatment and dosage changes during the study periods were recorded.
Statistical methods
The primary effect variable was the patient preference. A two-sided Prescott testS was used to investigate whether preferences could be referred to either the period or the treatment. As no statistically significant difference was found, the exact confidence limits for the p value were determined (binomial distribution). A 2 split-plot va riance analysis was used on the median visual analogue scale profiles for period and treatment effect. A Prescott test was per formed on adverse effects and drop outs. A Mann Whitney rank sum test was used to investigate whether the changes in sweating after the first and the second trial period were significantly different. Fisher's exact two-sided test was used in analysis of 2 x 2 contingency tables. A significance level of 5% was chosen.
Results

Prevalence of annoying HH in SCI
A total of 192 patients were given the questionnaire; 154 (80. 2%) answered (see Table I ). Eighty-seven patients had not ex perienced any sweating problems. Eleven had previous but not current problems: 6 reported that they had had very annoying HH 2-8 years after the spinal cord lesion; one reported a good effect of acupuncture; 2 that the sweating had disappeared after an operation for prostatic hypertrophy and one after having started intermittent catheterisa tion; and one reported that the HH had abruptly disappeared after a short period of treatment with epidural morphine.
Current HH problems were reported by 56 patients. Fifteen of the 56 answered that the sweating did not bother them or that they regarded it as a useful body signal, eg indicating too tight shoes, not being well seated, a too tightly fixed condom catheter, constipation or a full bladder. Thus, 41 patients reported annoying HH. In 13 of these a somatic cause was found to be possibly contributing: infections, dyspepsia, climacteric sweating, autonomic hyper reflexia, palindromic rheumatism, or sweat ing only in conjunction with micturition or defaecation. No contributing somatic cause could be found in 28 patients (14.6%) who indicated having annoying HH.
Study of the effect of D P During a 2 year period a total of 25 patients (see Table II ) were included from the 2 centres who are covering the rehabilitation function for all the SCI patients in Den mark. Nineteen patients completed the study, while 6 patients dropped out, due to unacceptable adverse effects during DP treatment (n = 5) or fear of such (n = 1). The patients who completed the study were 14 men and 5 women, age 20 to 78 years (median 36). The time since the lesion ranged from 2 months to 41 years (median 5 Table I Prevalence of hyperhidrosis years). The spinal cord lesions were located between C4 and L4. Eight patients had cervical lesions and all of them reported sweating above the level of the lesion. Fourteen had thoracic lesions and 7 of these had lesions above or at T6. Three patients had lumbar lesions. In most cases the sweating was located either in all the derma tomes proximal or distal to the level of the lesion. In some cases the sweating was not so well defined, but covered only parts of the corresponding areas (marked with * in Table II ). In patients with lesion levels below T9 the sweating tended to be more diffusely located (ie face, head, breast, axillae, trunk, or back). In 14 patients HH was most annoying during the day, and 17 patients had sweating at least once a day. There were no differences in the frequency of sweating between the patients with cerv ical or thoracic lesions. HH was significantly (p = 0.05) more annoying among cervical SCI compared with the lower lesions. There were no significant differences between treatment sequences, age, or gender, nor between patients from the 2 centres. There were no significant differences in the effects of DP among patients with proximal versus distal sweating or complete versus incom plete lesions.
Fifteen of the 19 patients had a prefer ence. Nine preferred the drug and 6 pre ferred placebo. There was no statistically significant difference between the 2 treat ments. The 95% confidence interval for the true proportion of patients who preferred DP, given that the patient had a preference, was 32-84%. Considering patients with SCI above or at the level of T6 only (the lowest level most often mentioned in which auton omic hyperreflexia has been seen), the corresponding interval was 40-97%. The possibility of an effect seems to be better in patients with a high SCI (see Fig 1) . Eight patients who preferred DP and 3 patients who preferred placebo wanted to continue treatment. This means that a net gain of 5 patients (8-3), ie 26% of those completing the study, was obtained with the active drug. Analysis of variance of the median visual analogue scale values showed a trend (p = 0.086-0.140) towards an effect of DP on sweating during the day. Adverse effects were recorded in 17 of the 25 patients included and in 12 of the 19 patients who completed the study. In the latter, adverse effects during DP treatment were experienced by 10 patients: lethargy, nausea, dyspepsia, dry mouth, dizziness, or difficulty in emptying bladder. There was a trend (p = 0.075) to an increased frequency of adverse effects during active therapy. All drop outs due to adverse effects occurred during DP administration (p = 0.056).
Eighteen of the 19 patients completing the study received other medical treatment, with an average number of 2.2 medicaments per patient. The medicaments given were: muscle relaxants (n = 8), anticonvulsants (n = 1), tricyclic antidepressants (n = 1), sedatives (n = 4), alpha-adrenoceptor anta gonists (n = 1), bladder muscle relaxants (n = 1), antibiotics (n = 4), diuretics (n = 2), urinary acidifying drugs (n = 4), laxatives (n = 7), and analgesics (n = 2). Some patients received 2 medicaments from the same pharmacological group. Figure 1 Patient preferences in relation to the level of the lesion. The 95% confidence interval for the true proportion of patients who pre ferred dextropropoxyphene hydrochloride, given that the patient had a preference, was for all the patients 32-84%. Considering only the patients with a level of the lesion above or at T6 the corresponding interval was 40-97% .
During the trial period 5 patients were started on antibiotic therapy. Whether in fections had any influence on preferences could not be judged.
Discussion
The prevalence of HH in SCI patients has not been investigated before to our know ledge. The frequency observed in the ques tionnaire study seems rather high, as HH was reported by 29% of the SCI patients, although only 14.6% found it annoying and had no contributing somatic cause. Patients with cervical lesions seem to have the most annoying sweating, which is consistent with previous findings. 6 Previously no controlled study had been performed for the treatment of annoying HH in SCI. The effect of DP in our study did not reach statistical significance but showed a trend towards effects, especially in patients with SCI at higher lesion levels. A statistically significant effect is probably difficult to achieve in this trial because of the limited number of patients included; the drop out frequency of 20%; and the relat ively high frequency of other somatic prob lems (ie frequent infections, pressure sores, bladder or bowel emptying problems) which probably results in a changing sweating pattern.
Considering that sweating can be very annoying and socially invalidating, that there are only few therapeutic possibilities for treatment, and that no serious adverse effects of DP was reported, we suggest that DP could be tried in individual cases of HH, especially in patients with SCI at or above T6 level.
The pathophysiological explanation for HH, which is most probably the same as reflex sweating,I , 7-1O is still partially ob scure. Changes in the autonomic nervous system and in sweating and temperature regulation in SCI have been the subject of several investigations, \ , 6 -9, 11 -14 and sweating has been found to represent an outstanding component of the symptoms of the spinal mass-reflex. 8 •14 In most cases reflex sweat ing or HH is probably mediated through the same mechanisms as autonomic hyperre flexia. 1 , 7
In patients with SCI the afferent impulses from below the level of the lesion enter the spinal cord via sympathetic, parasympa thetic, and somatosensory nerves through the dorsal nerve root and ascend along the spinothalamic tracts or the dorsal columns. At segmental levels up to the level of the lesion the impulses may cause a spinal mass-reflex, which has also been called autonomic hyperreflexia (or autonomic dys reflexia).6 The autonomic hyperreflexia/ dysreflexia has been suggested to be the result of sprouting of ascending fibres, forming abnormal synapses in the interme diolateral grey columns and resulting in a mass discharge of s l m R athetic neurons from peripheral stimuli. , 15 , 6 Eventually this sym pathetic outflow below the level of the lesion results in signs of sympathetic over activity, such as sweating, pilomotor spasm, and vasoconstriction in the splanchnic vas cular bed, the skin, and the legs. Due to the lack of supraspinal inhibition the vaso constriction persists, especially in patients with complete isolation of the sympathetic splanchnic outflow, as is the case for pati ents with cervical and high thoracic cord lesions (lesion level above T4). This can result in autonomic hyperreflexia with hypertension, bradycardia, and vasodilatation proximal to the level of the lesion. 2 , 7 ,9, 17 The lowest level most often mentioned in which autonomic hyperreflexia has been seen is T6,1 . 6 a level which is above most of the splanchnic sympathetic outflow, but even at levels down to Tll cases have been reported. 16 -18 The theoretical explanation for auto nomic hyperreflexia is supported by obser vations 8 of SCI patients in which bladder distention could elicit the characteristic changes in the autonomic nervous system. Sweating was seen as an outstanding feature induced by bladder distension. Almost any afferent impulse of visceral, cutaneous, or proprioceptive origin has been shown to provoke these changes,14 and the bladder and rectum have been found to be especially reflexogenic. 1 9 Furthermore, List and Pimenta 17 showed that bladder distension induced sweating could be abolished by regional block of the splanchnic nerves.
Characteristic sweating patterns were de scribed by Head and Riddoch 14 and were found to be dependent on the level of the lesion. Generally the sweating was most prominent in the most proximal parts, and tapered downward. Patients with cervical lesions had sweating in the head, neck, and arms. Sweating was seen only in the face and neck among patients with lesion levels above T3 level, and extended downwards below the level of the lesion. In patients with lesion levels below or at T9 level sweating was seen only distally to the level of the lesion.
The reasons for the sweating patterns seen in SCI patients are complex and partially unknown. It is still not completely understood 1 , 2 0 , 21 why patients with cervical and high thoracic SCI typically report the sweating to be located in the head, neck, and arms, ie the dermatomes above the level of the lesion. It seems that there is a higher degree of sympathetic activity in the proximal parts of the isolated cord, since it has been observed that the sweating in SCI with thoracic lesions is generally most active in the proximal parts just below the level of the lesion.1 , 17 For patients with cervical spinal lesions, the most proximal parts of the isolated spinal cord are the upper thoracic segments, and these segments (Tl-T7) are in turn those from which the eccrine sweat glands in the face, neck, and arms receive their sympathetic innervation, which could explain why patients with a high level of lesion typically sweat above the level. Thermoregulatory mechanisms are not responsible for sweating in cervical SCI, as this implies integrity of the sympathetic connections between the thermoregulatory centre in the hypothalamus and the sympa thetic efferent nerve fibres to the eccrine sweat glands which originate from the spinal cord segments between Tl-L2. 7 , 17 Circu lating catecholamines have in some reports been elevated during autonomic hyper reflexia 6 and could induce a weak noncho linergic sweat response in eccrine sweat glands. 22 In SCI patients with mid and lower thoracic lesion levels, sweating is often seen below the level and tapers downwards; this is explained by the same mechanism as for the cervical SCI. Sweating above the level of the lesion in thoracic SCI patients could be explained by normal thermoregulatory me chanisms23 , 24 activated either by a rise in the core temperature due to pilomotor spasms and vasoconstriction, or by circulating cate cholamines. 22 HH in patients with lumbar lesions is probably rare, but has been reported by Guttmann in a patient with conus/cauda equina syndrome. 1
The sweating pattern observed in our patients with cervical and higher thoracic lesion levels (Table II) is consistent \yith the observations by Head and Riddoch,14 Furthermore, our patients reported that sweating could also be induced by the stimuli which typically elicit autonomic hyperreflexia, It is our impression that HH in most of our patients (especially those with cervical and higher thoracic SCI) is elicited by the same mechanisms as the autonomic hyperreflexia.6 Therefore, before starting treatment for annoying HH, one should exclude treatable causes such as distension (constipation or urinary retention) or in flammation of visceral organs, infections, pressure sores, ingrown toe nails, etc.
Other rarer causes of HH have been reported and also need to be considered, ie post traumatic syringomyelia,25 orthostatic hypotension,26 and dural adhesions to the spinal cord. 1 0 . 27 It would be rational to use medicaments known to affect the mechanisms for reflex sweating and autonomic hyperreflexia. Pre viously, treatment of HH has been reported in uncontrolled trials, or in single cases with alpha-adrenoceptor antagonists, for inst ance phenoxybenzamine,28 cholinergic blocking drugs such as methantheline,25 and most recently hyoscine in a patch formulaReferences tion. 2 9 In view of the ill understood neurophysio logical mechanisms for HH, none of the above mentioned drugs is theoretically more suitable to use than any other. The main point in medical treatment of HH at this stage is to achieve a maximal therapeutic effect with minimal adverse effects, and we suggest that DP is worthwhile trying espe cially in patients with spinal cord injury above the level of T6.
